A new British Journal of Pharmacology review examines how phosphodiesterase-5 (PDE5) inhibitors, which were originally approved to treat erectile dysfunction, are finding clinical uses for a wide variety of conditions.
PDE5 inhibitors cause blood vessel dilation by targeting a particular cellular pathway that is involved in many normal physiological functions and in the pathophysiology of a wide range of diseases.
Source: Read Full Article